Filing Flows › Arcturus Therapeutics Holdings (ARCT) › Guidance & outlook

Arcturus Therapeutics Holdings (ARCT) guidance and outlook

Arcturus Therapeutics Holdings' 10-Q filed Nov 5, 2026 makes 18 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 5, 2026

• You should also review the factors and risks we describe in the reports we will file or submit from time to time with the Commission after the date of this report.
• Our proprietary LNP delivery system, LUNAR ® (“LUNAR”), is intended to address the major hurdle in RNA drug development, namely the effective and safe delivery of RNA to disease-relevant target tissues.
• Based on available data and FDA feedback, we plan to initiate dosing of ARCT-2601 in participants with OTC deficiency aged 12 years and older in Q1 2027 under an amended Phase 2 protocol that is expected to incorporate ARCT-2601 into the ongoing ARCT-810 Phase 2 study.
• We have expanded our mRNA therapeutics pipeline to include programs targeting phenylketonuria (PKU) and gout using the LUNAR 2.0™ platform.
• Through the acquisition, we obtained myNEO’s computational engine and related proprietary intellectual property, which we intend to use to enhance our mRNA design and target identification capabilities in antigen design, mRNA optimization and target identification, including to support pipeline development and expand strategic opportunities in oncology.
• As a result of the termination, the Company regained strategic control of its vaccine portfolio, including KOSTAIVE ® and its vaccine programs for seasonal influenza, pandemic influenza, respiratory syncytial virus (“RSV”) and Epstein-Barr virus (“EBV”), subject to ongoing arrangements with Meiji Seika Pharma (“Meiji”) for the Northern Hemisphere 2026-2027 season, which is expected to end on or around June 30, 2027.
• Beginning with the Northern Hemisphere 2027–2028 season, the Company expects to work directly with Meiji for KOSTAIVE ® activities in Japan.
• Expenses for both early-stage programs and discovery technologies are expected to increase slightly over the next twelve months as we continue to advance both our early- and later-stage programs.
• We believe the agreement may reduce our future cash requirements associated with the clinical development of ARCT-032 by funding a portion of those development activities, subject to the terms of the agreement.
• Our future capital requirements are difficult to forecast and will depend on many factors that are out of our control.
• If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected.
• There can be no assurance that we will be able to obtain additional needed financing on acceptable terms or at all.

Arcturus Therapeutics Holdings' latest quarter

Questions

What does Arcturus Therapeutics Holdings expect?

You should also review the factors and risks we describe in the reports we will file or submit from time to time with the Commission after the date of this report. Our proprietary LNP delivery system, LUNAR ® (“LUNAR”), is intended to address the major hurdle in RNA drug development, namely the effective and safe delivery of RNA to disease-relevant target tissues. Based on available data and FDA feedback, we plan to initiate dosing of ARCT-2601 in participants with OTC deficiency aged 12 years and older in Q1 2027 under an amended Phase 2 protocol that is expected to incorporate ARCT-2601 into

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.